Phase 2 Randomized, Noncomparative, Open-label Study of Aflibercept and Modified Folfox6 in the First-line Treatment of Metastatic Colorectal Cancer (affirm)

Research output: Contribution to journal › Meeting abstract › Contributed › peer-review

Contributors

  • Carles Pericay - , Autonomous University of Barcelona (Author)
  • Gunnar Folprecht - , Department of Internal Medicine I, TUD Dresden University of Technology (Author)
  • Mark Saunders - , The Christie NHS Foundation Trust (Author)
  • Anne Thomas - , University of Leicester (Author)
  • Jae Kyung Roh - , Yonsei University (Author)
  • Rafael Lopez - , University Clinical Hospital of Santiago de Compostela (Author)
  • Thomas Hoehler - (Author)
  • Jun Suk Kim - , Korea Maritime and Ocean University (Author)
  • Chiara Zilocchi - , Sanofi Germany GmbH (Author)
  • Emmanuelle Boelle - , Sanofi Germany GmbH (Author)
  • John Zalcberg - , Peter Maccallum Cancer Centre (Author)

Details

Original languageGerman
Pages (from-to)16-16
Number of pages1
JournalAnnals of oncology
Volume23
Publication statusPublished - Jun 2012
Peer-reviewedYes

Conference

Title14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO)
Duration27 - 30 June 2012
CityBarcelona
CountrySpain

External IDs

ORCID /0000-0002-9321-9911/work/142252022

Keywords

Sustainable Development Goals